CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?
<b>Background</b>: Patients with refractory and relapsed acute myeloid leukemia (R/R AML) face a dismal prognosis. CAR-T therapy has emerged as a potential treatment option. This study assesses the available clinical evidence on CAR-T in R/R AML, focusing on safety and efficacy outcomes....
Saved in:
Main Authors: | Pilar Lloret-Madrid, Pedro Chorão, Manuel Guerreiro, Pau Montesinos |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-05-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/32/6/322 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Treatment of pediatric relapsed and refractory acute myeloid leukemia
by: F. A. Makhacheva, et al.
Published: (2023-05-01) -
Combination of hypomethylating agents and inhibitor of BCL-2 in treatment of patients with relapsed acute myeloid leukemia: S.P. Botkin hospital experience
by: M. A. Granatkin, et al.
Published: (2023-03-01) -
Older Jehovah’s Witnesses with Acute Myeloid Leukemia: Hypomethylating Agents and Venetoclax as a Transfusion-Sparing Approach
by: Aditi Sharma, et al.
Published: (2025-06-01) -
Clinical and genetic characteristics of acute myeloid leukemia with t(8;21) in children and results of therapy according to protocol AML-MM-2000
by: I. I. Kalinina, et al.
Published: (2014-07-01) -
Comparative characteristics of quantitative and structural chromosome abnormalities at the time of diagnosis and in relapses of acute myeloid leukemias
by: S.V. Andreieva, et al.
Published: (2025-06-01)